Literature DB >> 31712212

Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus.

Aubrey Watson1, Karen Sauve1, Cara Cassino1, Raymond Schuch2.   

Abstract

In vitro synergy between an antimicrobial protein lysin (cell wall hydrolase) called exebacase and each of 12 different antibiotics was examined against Staphylococcus aureus isolates using a nonstandard medium approved for exebacase susceptibility testing by the Clinical and Laboratory Standards Institute. In the checkerboard assay format, fractional inhibitory concentration index values of ≤0.5, consistent with synergy, were observed for the majority of interactions tested. Synergy was further confirmed in time-kill assays.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CF-301; MRSA; Staphylococcus aureuszzm321990; direct lytic agent; exebacase; lysin; synergy

Mesh：

Substances：

Year:  2020        PMID： 31712212      PMCID： PMC6985718          DOI： 10.1128/AAC.01885-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis.

Authors:  Chiara Indiani; Karen Sauve; Assaf Raz; Wessam Abdelhady; Yan Q Xiong; Cara Cassino; Arnold S Bayer; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments.

Authors:  Michael Wittekind; Raymond Schuch
Journal:  Curr Opin Microbiol       Date:  2016-05-31       Impact factor: 7.934

4.  Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent.

Authors:  Raymond Schuch; Babar K Khan; Assaf Raz; Jimmy A Rotolo; Michael Wittekind
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis.

Authors:  Aubrey Watson; Jun Taek Oh; Karen Sauve; Patricia A Bradford; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

6.  Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus.

Authors:  Patricia Letrado; Bruno Corsini; Roberto Díez-Martínez; Noemí Bustamante; José E Yuste; Pedro García
Journal:  Future Microbiol       Date:  2018-09-21       Impact factor: 3.165

7.  Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.

Authors:  Raymond Schuch; Han M Lee; Brent C Schneider; Karen L Sauve; Christina Law; Babar K Khan; Jimmy A Rotolo; Yuki Horiuchi; Daniel E Couto; Assaf Raz; Vincent A Fischetti; David B Huang; Robert C Nowinski; Michael Wittekind
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226
  7 in total
  14 in total

1.  Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.

Authors:  Vance G Fowler; Anita F Das; Joy Lipka-Diamond; Raymond Schuch; Roger Pomerantz; Luis Jáuregui-Peredo; Adam Bressler; David Evans; Gregory J Moran; Mark E Rupp; Robert Wise; G Ralph Corey; Marcus Zervos; Pamela S Douglas; Cara Cassino
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.

Authors:  Dario Lehoux; Arnold S Bayer; Sonia U Shah; Yan Q Xiong; Wessam Abdelhady; James Iwaz; Youngju Pak; Raymond Schuch; Cara Cassino
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model.

Authors:  Tomefa E Asempa; Kamilia Abdelraouf; Teresa Carabeo; Raymond Schuch; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Exebacase in Addition to Daptomycin against MRSA.

Authors:  Razieh Kebriaei; Kyle C Stamper; Katherine L Lev; Taylor Morrisette; Jacinda C Abdul-Mutakabbir; Raymond Schuch; Dario Lehoux; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

5.  Arthroscopic "Debridement and Implant Retention" With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection.

Authors:  Tristan Ferry; Cécile Batailler; Aubin Souche; Cara Cassino; Christian Chidiac; Thomas Perpoint; Claire le Corvaisier; Jérôme Josse; Romain Gaillard; Julien Roger; Camille Kolenda; Sébastien Lustig; Frédéric Laurent
Journal:  Front Med (Lausanne)       Date:  2021-05-14

6.  Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins.

Authors:  Ana Gouveia; Daniela Pinto; Helena Veiga; Wilson Antunes; Mariana G Pinho; Carlos São-José
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

Review 7.  Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance.

Authors:  Raymond Schuch; Cara Cassino; Xavier Vila-Farres
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

8.  Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity.

Authors:  Maria M Traczewski; Jane E Ambler; Raymond Schuch
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

9.  Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.

Authors:  Jun T Oh; Jane E Ambler; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

10.  Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection.

Authors:  Steven M Swift; Karen Sauve; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.